Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1972 Aug 5;107(3):203–209.

Comparative bioavailability of three brands of ampicillin

C MacLeod, H Rabin, J Ruedy, M Caron, D Zarowny, R O Davies
PMCID: PMC1940893  PMID: 5052904

Abstract

The relative biological availability (bioavailability) of three brands of ampicillin trihydrate capsules marketed in Canada was studied by means of a crossover experimental design and was evaluated by analysis of variance. After administration of a single oral dose (500 mg.) to volunteer subjects, the mean peak ampicillin serum concentration and the area under the time ampicillin serum concentration curve (AUC) were higher for one of the products than for the other two. A second study utilizing the same experimental design revealed no differences in these parameters when different production lots of the more available product were compared. Product bioavailability was not related to the in vitro dissolution time of the capsules. The experimental design and methods of statistical analysis are discussed.

Full text

PDF
203

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barr W. H., Gerbracht L. M., Letcher K., Plaut M., Strahl N. Assessment of the biologic availability of tetracycline products in man. Clin Pharmacol Ther. 1972 Jan-Feb;13(1):97–108. doi: 10.1002/cpt197213197. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Lindenbaum J., Mellow M. H., Blackstone M. O., Butler V. P., Jr Variation in biologic availability of digoxin from four preparations. N Engl J Med. 1971 Dec 9;285(24):1344–1347. doi: 10.1056/NEJM197112092852403. [DOI] [PubMed] [Google Scholar]
  4. Schneller G. H. Status report on drug bio-availability. Am J Hosp Pharm. 1970 Jun;27(6):485–488. [PubMed] [Google Scholar]
  5. Van Petten G. R., Feng H., Withey R. J., Lettau H. F. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations. J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):177–186. [PubMed] [Google Scholar]
  6. Wagner J. G., Welling P. G., Lee K. P., Walker J. E. In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci. 1971 May;60(5):666–677. doi: 10.1002/jps.2600600503. [DOI] [PubMed] [Google Scholar]
  7. Withey R. J., Feng H., Cook D., Van Petten G. R., Lettau H. F. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters. J Clin Pharmacol New Drugs. 1971 May-Jun;11(3):187–196. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES